ArticleUnited European gastroenterology journal2024

Analysis of tofacitinib safety in ulcerative colitis from the completed global clinical developmental program up to 9.2 years of drug exposure.

Julian Panés et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.